Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

Spojené štáty - angličtina - NLM (National Library of Medicine)

sagent pharmaceuticals - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin injection is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radio therapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. cisplatin is contraindicated in patients with pre-existing renal impairment. cisplatin should not be employed in myelosuppressed patients, or in patients with hearing impairment. cisplatin is contraindicated in patients with a history of allergic reactions to cisplatin or other platinum containing compounds.

Spojené štáty - angličtina - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin injection is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin injection and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. cisplatin is contraindicated in patients with pre-existi

Spojené štáty - angličtina - NLM (National Library of Medicine)

mylan institutional llc - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - cisplatin 1 mg/ml - solution for injection - 1 mg/ml - active: cisplatin 1 mg/ml excipient: hydrochloric acid sodium chloride water for injection - cisplatin ebewe is indicated as palliative therapy to be employed as follows: metastatic non-seminomatous germ cell carcinoma: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic non-seminomatous germ cell tumours who have already received appropriate surgical and/or radiotherapeutic procedures. metastatic ovarian tumours: cisplatin ebewe, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumours refractory to standard chemotherapy who have not previously received cisplatin ebewe therapy. advanced and refractory carcinoma of the bladder: cisplatin ebewe, as a single agent, is indicated as secondary therapy in patients with advanced stage bladder cancer refractory to standard chemotherapy who have not previously received cisplatin ebewe therapy. squamous cell carcinoma of the head and neck (refractory to standard chemotherapy): cisplatin ebewe, as a single agent, is indicated as secondary therapy in patients with squamous cell carcinoma of the head and neck refractory to standard chemotherapy who have not previously received cisplatin ebewe therapy.

Spojené štáty - angličtina - NLM (National Library of Medicine)

wg critical care, llc - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin for injection is indicated for the treatment of advanced testicular cancer. cisplatin for injection is indicated for the treatment of advanced ovarian cancer. cisplatin for injection is indicated for the treatment of advanced bladder cancer. cisplatin for injection is contraindicated in patients with severe hypersensitivity to cisplatin [see warnings and precautions (5.4)] . risk summary based on human data from published literature, cisplatin for injection can cause fetal harm when administered to pregnant women. advise pregnant women and females of reproductive potential of the potential risk to a fetus. data demonstrates transplacental transfer of cisplatin. exposure of pregnant women to cisplatin-containing chemotherapy has been associated with oligohydramnios, intrauterine growth restriction, and preterm birth. cases of neonatal acute respiratory distress syndrome, cytopenias, and hearing loss have been reported. cisplatin for injection administration to animals during and after organogenesi

Spojené štáty - angličtina - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml

Malta - angličtina - Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents

Malta - angličtina - Medicines Authority

fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents